ABSTRACT AMP-activated protein kinase (AMPK) is a heterotrimeric kinase that regulates cellular energy metabolism by affecting energy-consuming pathways such as de novo lipid biosynthesis and glucose production as well as energyproducing pathways such as lipid oxidation and glucose uptake. Accordingly, compounds that activate AMPK represent potential drug candidates for the treatment of hyperlipidemia and type 2 diabetes. Screening of a proprietary library of AMP mimetics identified the phosphonic acid 2 that bears little structural resemblance to AMP but is capable of activating AMPK with high potency (EC 50 = 6 nM vs AMP EC 50 = 6 μM) and specificity. Phosphonate prodrugs of 2 inhibited de novo lipogenesis in cellular and animal models of hyperlipidemia.
D
iseases associated with obesity, such as type 2 diabetes, hypertension, and dyslipidemia, are growing worldwide health concerns. These conditions are frequently associated with impaired regulation of glucose and lipid metabolism, leading to increased cardiovascular risks. Current therapies for the treatment of dyslipidemia and type 2 diabetes are only moderately effective, and even in combination, many patients still do not meet the recommended guidelines. 1 Therefore, new pharmacological approaches that can address one or multiple components related to these diseases are under investigation. One approach that has recently elicited considerable interest is the activation of 5 0 -AMP-activated protein kinase (AMPK).
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AMPK is a heterotrimeric kinase expressed in a variety of tissues, particularly the liver, brain, and skeletal muscle. It has been dubbed a "metabolic master switch" 6 that putatively regulates fatty acid synthesis, sterol synthesis, and glucose production. 7 AMPK acts as an energy sensor that is activated by AMP under conditions where the intracellular ratio of AMP to ATP is increased, such as hypoxia, exercise, or glucose deprivation. As a result of this activation, processes where ATP is consumed (e.g., fatty acid synthesis, gluconeogenesis, and cholesterol synthesis) are inhibited through targets downstream of AMPK, while pathways where ATP is generated (e.g, fatty acid oxidation, ketogenesis, and glycolysis) are stimulated, resulting in restoration of energy homeostasis. Because of its important role in the regulation of lipid and carbohydrate metabolism, activators of AMPK could potentially provide a multifaceted approach to the treatment of metabolic diseases.
5-Aminoimidazole-4-carboxamide riboside (AICAR) is a nucleoside that undergoes intracellular phosphorylation to the corresponding 5 0 -mono-, di-, and triphosphate (Chart 1). AICAR-monophosphate (ZMP) is an AMP mimetic that binds to AMP binding sites on various intracellular proteins 8, 9 and induces the associated functional response such as inhibition of fructose-1,6-bisphosphatase and the activation of glycogen phosphorylase (GPPase).
10 While ZMP is a modestly potent and poorly selective activator of AMPK, it has been used in hundreds of studies attempting to elucidate the role of AMPK in energy homeostasis. [11] [12] [13] [14] [15] [16] In addition, it has been suggested that AMPK activation may contribute to the glucose-lowering activity of marketed diabetes drugs metformin 17 and the thiazolidinediones. 18, 19 These findings as well as the report of a specific AMPK activator 20, 21 (A-769662, 1) suggest that a small molecule activator of AMPK may be a viable approach to treat diseases associated with dysregulation of energy homeostasis.
Herein, we disclose the discovery of compound 2, a potent and selective activator of human AMPK. We also report the synthesis of esterase-sensitive phosphonate prodrugs of 2 and demonstrate the ability of these compounds to inhibit de novo lipogenesis in rat hepatocytes and in rodents.
Compound 2 was identified as a potent activator of AMPK after screening a proprietary library containing ca. 1200 AMP mimetics. Its synthesis is depicted in Scheme 1. The diethyl aldehyde 3 8 was deprotected using bromotrimethylsilane in acetonitrile at room temperature. The resulting phosphonic acid 4 was reprotected as the dibenzyl phosphonate using the DCC adduct of benzyl alcohol in DMF/toluene. 22 The crude aldehyde was converted to a mixture of isomeric oximes (cis/trans, 34% yield over two steps) by treatment with hydroxylamine hydrochloride. Chlorination of the intermediate oximes with N-chlorosuccinimide (NCS) in DMF yielded chlorooxime 5 (88%). [3 þ 2] Cycloaddition of 5 with benzyloxyacetylene 23 regioselectively produced isoxazole 6. Hydrogenation of 6 using palladium hydroxyde on carbon in ethanol in the presence of N,N-dicyclohexylamine gave compound 2.
Alternatively, chlorooxime 7 (prepared from 3 using the methods described above) was used to generate the diethylphosphonate analogue 8 by reaction with Meldrum's acid in dichloromethane (Scheme 2). However, attempts to remove the ethyl groups in phosphonate 8 under a variety of reaction conditions failed to yield phosphonic acid 2, generating instead a complex mixture of products.
While the diethyl phosphonate 8 was not an AMPK activator, it was a useful tool compound that allowed us to evaluate some of the properties of the 5-hydroxyisoxazole portion of the molecule. The hydroxyisoxazole ring of 8 exists in the keto form in CDCl 3 , as determined by proton NMR, which shows a 2H signal at 3.81 ppm corresponding to the methylene group (C-4) of the isoxazolone ring. However, in DMSO-d 6 , also 8 exists as the enol form, as indicated by the presence of two 1H signals at 5.60 and 4.20 ppm. Compound 9, the 13 C-labeled version of 8, was similarly generated by using 5- CNMR spectrum of 9 in the same solvent showed a signal at 33.85 ppm. When 9 was dissolved in DMSO-d 6 , it showed two signals at 77.27 and 34.25 ppm, indicating the presence of both the enol and the keto form, respectively, in this solvent. The addition of triethylamine to this solution caused the complete disappearance of these two signals and the appearance of a single peak at 67.11 ppm, suggesting that conversion to the triethylammonium enolate of the hydroxyisoxazole ring in DMSO-d 6 had occurred. In an aqueous solution of sodium hydroxide (pH > 10), the 13 C NMR of 9 showed a single peak at 71.37 ppm, again indicating the presence of the enolate form of 9 in this highly basic medium. The 13 C NMR spectrum of 9 in pH 7.4 phosphate buffer also shows a single peak at 71.37 ppm, indicating that it exists almost exclusively as the enolate under these conditions. This keto-enol tautomerization is evidence of the relatively high acidity of the 5-hydroxyisoxazole group. Indeed, potentiometric titration of 8 in mixtures of methanol/water provided pK a values of 3.23. Similarly, potentiometric titration of 2 in the same solvent revealed pK a values of 3.32, 3.93, and 6.94. Consistent with these findings, the log D 7.4 for 2 was found to be -4.3.
The highly anionic nature of 2 was an impediment for its transport across cell membranes and likely was responsible for its lack of effect in cell-based and in vivo models; thus, prodrug strategies were explored 27 to improve cell penetration for compound 2.
For the synthesis of esterase-sensitive prodrugs of 2, the formal [3 þ 2] cycloaddition reaction using Meldrum's acid was utilized. Scheme 3 illustrates the application of this method to the synthesis of compound 12, a bis-pivaloyloxymethyl (bis-POM) prodrug of 2. Alkylation of 4 with the pubs.acs.org/acsmedchemlett iodomethyl ester of pivalic acid in the presence of Hunig's base generated 10. Chlorooxime 11 was generated from 10 in two steps: oxime formation by reaction with 1.05 equiv of hydroxylamine hydrochloride and sodium acetate, followed by conversion to 11 by reaction with NCS in DMF. Cycloaddition with Meldrum's acid gave the desired prodrug 12. This method was used for the synthesis of additional prodrugs (compounds 13-18, Table 1 ) where the phosphonic acid was functionalized with other esterase sensitive groups.
Compound 2 was identified by screening a library of proprietary AMP mimetics 8 against both human and rat AMPK by monitoring the phosphorylation of the SAMS peptide, an extensively utilized substrate for AMPK. 24 Compound 2 was found to be a full activator of human AMPK, with an EC 50 of 6.3 nM (Figure 1) , which is >900-fold more potent than the endogenous activator AMP (EC 50 = 5.9 μM). The potency of 2 is similar against rat AMPK (EC 50 = 21 nM), but interestingly, it was a partial activator of rat AMPK, reaching a maximum of 51% of the activation observed with AMP. In selectivity assessments, screening of 2 against a panel of 64 targets (MDS Pharma Services) indicated no significant interactions with these targets at a test concentration of 10 μM.
AMP allosterically modulates other key enzymes: It activates GPPase (EC 50 = 1.4 μM), while it inhibits FBPase (IC 50 = 1.0 μM). ZMP is an AMP mimic that activates rat liver AMPK with an EC 50 = 84 μM. However, it is not specific toward AMPK. For example, it activates GPPase with an EC 50 = 115 μM and inhibits FBPase with an IC 50 = 9.4 μM. In contrast, 2 had no activity against GPPase and FBPase at concentrations of 100 μM, about 1000-fold its EC 50 for activation of AMPK. These results suggest that, unlike ZMP, 2 is a selective AMPK activator.
Compounds 8 and 12 were not activators of the isolated enzyme, suggesting that the phosphonic acid group was essential for the in vitro activation of AMPK by 2. Acetyl-CoA carboxylase (ACC) catalyzes the rate-limiting step in free fatty acid biosynthesis. Phosphorylation of ACC by AMPK decreases its activity, resulting in a reduction in the ACC product malonylCoA and, correspondingly, in the inhibition of de novo lipogenesis. Because malonyl-CoA is a potent inhibitor of carnitine pubs.acs.org/acsmedchemlett palmitoyltransferase-1 (CPT-1), activation of AMPK also results in inactivation of CPT-1 and in an increase in free fatty acid oxidation. In addition to its effects on fatty acid production and metabolism, AMPK activation also results in the phosphorylation of HMGCoA reductase and, consequently, in the inhibition of cholesterol biosynthesis. 25, 26 To evaluate the effect of 2 on de novo lipogenesis, plated rat hepatocytes were incubated with the test compound and then coincubated with 14 C-sodium acetate as a lipogenic substrate. De novo lipogenesis was evaluated by measuring the radiolabeled counts coming from 14 C-acetate incorporated into organic soluble lipids. Compound 2 did not affect de novo lipogenesis in primary rat hepatocytes (data not shown). The highly anionic nature of 2 suggested that its lack of activity may have been due to poor cellular permeability. Indeed, upon incubation of plated rat hepatocytes with 2, at a concentration of 100 μM for up to 6 h, the intracellular levels of 2 were below the limits of detection (55 nmol/g). To improve cell permeability, the phosphonic acid group was masked with esterase-sensitive prodrugs. 27 Incubation of plated rat hepatocytes with a 10 or 100 μM solution of 12 led to 254 ( 104 and 2151 ( 712 nmol/g intracellular concentrations of 2, respectively, after a 2 h incubation period. The levels of 2 were maintained at >180 nmol/g for up to 8 h and detected as early as 15 min (see the Supporting Information).
Shown in Table 1 are ester and carbonate prodrugs of 2 that inhibited de novo lipogenesis in plated rat hepatocytes with EC 50 values below 1 μM. Given that the prodrug 12 is not an activator of isolated AMPK (data not shown), these results are consistent with conversion to 2 by intracellular esterases. It is clear from the data that relatively unhindered esters and carbonates had very similar potencies in this assay, reflecting similar rates of intracellular generation of 2 and subsequent AMPK activation in plated rat hepatocytes.
As evidence pointing to the activation of AMPK as the source of the inhibition of the de novo lipogenesis, we evaluated the ability of compound 13 to induce phosphorylation of ACC. Primary plated rat hepatocytes were incubated for a 4 h period with 13 (1, 3, and 10 μM) or AICAR (1000 μM) as the positive control. Immunoblot analysis of the lysate using a specific antibody that recognizes ACC phosphorylated at serine-79 shows increased phosphorylation of ACC (Figure 2 ). There was no change in total ACC protein levels following treatment with either of the agents used, reprobing the blot with a total ACC antibody, or in total protein loaded by staining the blot with Ponceau S (data not shown). These results are consistent with the activation of AMPK as the source for the inhibition of the de novo lipogenesis.
To determine whether the cellular effects of compounds 12-18 would translate to the in vivo setting, de novo lipogenesis was measured in mice following treatment with potential AMPK activators. Because preliminary results showed that oral dosing of prodrugs 12-18 resulted in low plasma levels of 2 as well as the corresponding prodrugs (data not shown), the compounds were administered by intraperitoneal injection. Compounds were dosed (generally 30-100 mg/kg) 1 h prior to intraperitoneal administration of 14 C-sodium acetate in saline. One hour later, animals were anesthetized, and plasma and liver were harvested. Newly synthesized lipids and sterols were extracted using a modified Folch method 28 and quantified relative to those in vehicle-treated mice. At a dose of 30 mg/kg, compounds 12-17 achieved plasma concentrations of 200-300 μM and inhibited de novo lipogenesis by more than 30% ( Table 1 ).
In conclusion, we have described the synthesis and evaluation of 2, a furan phosphonic acid derivative containing an acidic 5-hydroxyisoxazole group. Compound 2 activates AMPK with an impressive EC 50 < 10 nM and is the most potent direct AMPK activator reported to date. [29] [30] [31] Esterasesensitive prodrugs of 2 enhanced the intracellular delivery of this highly anionic compound into hepatocytes. These tool compounds inhibited de novo lipogenesis both in plated rat hepatocytes and in mice. It should be noted that while 2 is only a partial activator of rat liver AMPK, it was able to fully inhibit de novo lipogenesis in rat hepatocytes. Given the high specificity of compound 2 relative to ZMP, prodrugs of 2, for example, 12-18, may be useful tools to elucidate the role that AMPK activation plays in whole body energy homeostasis. Additional studies are ongoing that utilize these and related compounds in disease-relevant models to understand the therapeutic potential of AMPK activators. 
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